Spinal Elements Reports Expansion of MIS Ultra™ Offering with the Full Market Release of the Lucent® XP Wide Expandable Device for MIS TLIF

Spinal Elements, a spine technology company, today announced the newest introduction in its MIS Ultra™ suite of products with the full release of the Lucent® XP Wide expandable interbody device. This addition to Spinal Elements’ expandable interbody portfolio offers surgeons a wider footprint option than previously available and is designed with an anatomically oriented lordotic angle.

Spinal Elements notes the system is optimized to be used in MIS TLIF (transforaminal lumbar interbody fusion) procedures, but can also be used in open TLIF procedures.

With this expanded commercial release, Spinal Elements adds to the increasing number of procedural solutions within their MIS Ultra platform of products. The company’s line of expandable devices has shown rapid adoption and growth over the past year, and the company plans on further line additions to the Lucent XP offering, as well as other expandable interbody technologies to complement the MIS Ultra platform.

The Lucent XP Wide System is an interbody device with an anatomically oriented lordotic design that can expand in height and increase in lordosis after implantation. The height expansion helps restore the height of the disc space, while the lordotic angle helps correct the natural curvature of the spine. With the Lucent XP Wide device, surgeons can achieve up to 15 degrees of lordotic angle, while helping to improve spinal stability and alignment.

In addition, the Lucent XP Wide system is the only available expandable device that it is made primarily of polyetheretherketone (PEEK) and features Spinal Elements’ Ti-Bond® porous titanium coating. Ti-Bond is a hydrophilic porous titanium coating with nano-scale surface features that has been used in tens of thousands of Spinal Elements fusion procedures dating back to 2012.

Orthopedic Spine Surgeon and designer, Paul Kim, MD of the Spine Institute of San Diego, CA, says of the Lucent XP Wide System: “With oblique lordosis in the design, I am able to achieve expansion and lordosis in the midline, instead of asymmetrical lordosis. The system also allows me to place a large TLIF cage in a narrow corridor in patients with a collapsed disc without disruption of the exiting nerve root. I am a big believer in MIS TLIF and this system addresses some of the challenges that can be seen in these surgeries.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”